Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Chem Biodivers ; 18(10): e2100504, 2021 Oct.
Article in English | MEDLINE | ID: mdl-34409724

ABSTRACT

The present study illustrates the design and synthesis of new series of 3-trifluoromethylpyrazole tethered chalcone-pyrrole and pyrazoline-pyrrole derivatives. All compounds were further screened for in vitro cytostatic activities on full NCI 60 cancer cell lines at National Cancer Institute, USA. Compounds (2E)-3-(1H-pyrrol-2-yl)-1-{4-[3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}prop-2-en-1-one (5a) and (2E)-1-{3-methyl-4-[3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-3-(1H-pyrrol-2-yl)prop-2-en-1-one (5c) displayed significant antiproliferative activity (Growth Percentage: -77.10 and -92.13, respectively at 10 µM concentration) against the UO-31 cell lines from renal cancer and were further selected for assay at 10-fold dilutions of five different concentrations (10-4 to 10-8  M). Both compounds 5a and 5c exhibited promising antiproliferative activity (GI50 : 1.36 to 0.27 µM) against leukemia cancer cell lines HL-60 and RPMI-8226, colon cancer cell lines KM-12; breast cancer cell lines BT-549. Moreover, both compounds 5a and 5c were found to be non-cytotoxic (LC50 >100) against HL-60, RPMI-8226, and KM-12 cell lines. Remarkably, GI50 values of compounds 5a and 5c were identified as more promising than sunitinib against most cancer cell lines. In silico study of compounds 5a and 5c exemplified the desired ADME properties for drug-likeness as well as tighter interactions with VEGFR-2. Hence, compounds 5a and 5c would be good cytotoxic agents after further clinical study.


Subject(s)
Antineoplastic Agents/pharmacology , Chalcone/pharmacology , Pyrazoles/pharmacology , Pyrroles/pharmacology , Antineoplastic Agents/chemical synthesis , Antineoplastic Agents/chemistry , Cell Line, Tumor , Cell Proliferation/drug effects , Chalcone/chemistry , Dose-Response Relationship, Drug , Drug Screening Assays, Antitumor , Humans , Molecular Structure , Pyrazoles/chemical synthesis , Pyrazoles/chemistry , Pyrroles/chemistry , Structure-Activity Relationship
2.
Int J Biol Macromol ; 167: 906-920, 2021 Jan 15.
Article in English | MEDLINE | ID: mdl-33186648

ABSTRACT

The research work was intended to formulate teriflunomide (TFM) loaded nano lipid-based (TNLC) carbopol-gellan gum in situ gel (TNLCGHG) and to investigate its therapeutic efficacy against glioma, a brain and spine tumor. Nanoformulation was developed using gellan gum and carbopol 974P as gelling and mucoadhesive agents, respectively, Glyceryl di-behenate and Glyceryl mono-linoleate blend as lipids, and Gelucire 44/14: water blend as surfactant system. Globule size, PDI, zeta potential, encapsulation efficiency, mucoadhesive strength, and nasal permeation were found to be 117.80 nm, 0.56, -21.86 mV, 81.16%, 4.80 g, and 904 µg/cm2, respectively. Anticancer efficacy of TFM-loaded nano lipid-based carbopol-gellan gum in situ gel (TNLCGHG) was determined in human U-87MG glioma cell line. IC50 was found 7.0 µg/mL for TNLCGHG, 4.8 µg/mL for pure TFM, and 78.5 µg/mL for TNLC, which approve the superiority of surfactant along with gellan gum as permeation enhancer. Brain Cmax for technetium (99mTC) labeled intranasal (i.n.) 99mTC-TNLCGHG was found 2-folds higher than 99mTC-TNLC (i.n.) and 99mTC-TNLC intravenous (i.v.) because the TNLCGHG formulation contains surfactant with natural gelling polymers, which promisingly improved drug permeability. Finally, this research revealed encouraging outcomes and successfully developed intranasal TNLCGHG nanoformulation as a novel tool for safe delivery of TFM in glioma patients.


Subject(s)
Acrylic Resins/chemistry , Crotonates/administration & dosage , Drug Carriers/chemistry , Drug Delivery Systems , Lipids/chemistry , Nanogels/chemistry , Polysaccharides, Bacterial/chemistry , Toluidines/administration & dosage , Administration, Intranasal , Animals , Brain/drug effects , Brain/metabolism , Calorimetry, Differential Scanning , Cell Line, Tumor , Chemical Phenomena , Chromatography, High Pressure Liquid , Glioma/drug therapy , Hydroxybutyrates , Nanoparticles/chemistry , Nitriles , Particle Size , X-Ray Diffraction
3.
Arch Pharm (Weinheim) ; 354(2): e2000267, 2021 Feb.
Article in English | MEDLINE | ID: mdl-33078449

ABSTRACT

A potential molecular hybridization strategy was used to develop 24 novel pyrazoline-conjugated 2,4-dimethyl-1H-pyrrole-3-carboxylic acid and amide derivatives. The preliminary in vitro antimicrobial assay delivered four potential derivatives with growth inhibition in the range of 50.87-56.60% at the concentration of 32 µg/ml. In the search of an anticancer candidate, all derivatives were screened by NCI-60 at 10 µM concentration, revealing that 12 derivatives were potential agents against the various types of cancer cell lines, with growth inhibition in the range of 50.21-108.37%. The in vitro cytotoxicity assay against the cell line HEK293 (human embryonic kidney cells) and the hemolysis assay of the representative potent compounds propose their potential for a good therapeutic index. In silico studies of the most potent derivatives qualified their significant pharmacokinetic properties with good predicted oral bioavailability and their adherence to Lipinski's rule of five for druglikeness. A molecular docking study against VEGFR-2 with the best-scored conformations reinforced their anticancer potency. The docking study of the most potent compound against VEGFR-2 with the best-scored conformations displayed a binding affinity (-9.5 kcal/mol) comparable with the drug sunitinib (-9.9 kcal/mol) and exhibited that tighter interactions at the active adenosine triphosphate site might be responsible for anticancer potency.


Subject(s)
Anti-Bacterial Agents/pharmacology , Antineoplastic Agents/pharmacology , Carboxylic Acids/pharmacology , Pyrazoles/pharmacology , Pyrroles/pharmacology , Anti-Bacterial Agents/chemical synthesis , Anti-Bacterial Agents/chemistry , Antineoplastic Agents/chemical synthesis , Antineoplastic Agents/chemistry , Carboxylic Acids/chemistry , Cell Line , Cell Proliferation/drug effects , Dose-Response Relationship, Drug , Drug Screening Assays, Antitumor , Fungi/drug effects , Gram-Negative Bacteria/drug effects , Gram-Positive Bacteria/drug effects , Humans , Microbial Sensitivity Tests , Molecular Docking Simulation , Molecular Structure , Pyrazoles/chemistry , Pyrroles/chemistry , Structure-Activity Relationship
4.
Bioorg Chem ; 97: 103660, 2020 04.
Article in English | MEDLINE | ID: mdl-32086056

ABSTRACT

A new series of 2,4-dimethyl-1H-pyrrole-3-carboxamide derivatives bearing benzimidazole moiety was synthesized through a molecular hybridization approach and evaluated for in vitro anticancer activity by NCI-60 on leukemia, melanoma, lung, colon, CNS, ovarian, renal, prostate and breast cancer cell lines at a single dose (10 µM). Among all the synthesized conjugates, some derivatives showed more or less good activity even at such a small dose, while, compound 5-(1H-benzo[d]imidazol-2-yl)-N-(1-cyclohexylethyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (8f) displayed significant antiproliferative activity specifically against MDA-MB human cancer cell lines. Compound 8f showed promising activity against MDA-MB-435 cell line of melanoma (Growth inhibition: 62.46%) and MDA-MB-468 cell line of breast (Growth inhibition: 40.24%). Computational ADME study qualified its significant physicochemical, pharmacokinetic and drug-likeness properties with good predicted oral bioavailability. Thus this new hybrid molecules would be useful for further anticancer drug development.


Subject(s)
Antineoplastic Agents/chemistry , Antineoplastic Agents/pharmacology , Benzimidazoles/chemistry , Benzimidazoles/pharmacology , Drug Design , Cell Line, Tumor , Cell Proliferation/drug effects , Drug Screening Assays, Antitumor , Humans , Methylation , Models, Molecular , Neoplasms/drug therapy , Pyrroles/chemistry , Pyrroles/pharmacology , Structure-Activity Relationship
5.
ACS Omega ; 4(5): 8522-8527, 2019 May 31.
Article in English | MEDLINE | ID: mdl-31459942

ABSTRACT

A novel heterogeneous catalytic method was developed for the synthesis of coumarin and its derivatives using the Ti(IV)-doped ZnO matrix forming catalyst Zn0.925Ti0.075O having a high surface area and good Lewis acidity. The catalyst shows high activity toward a broad spectrum of the substituted phenols with ß-ketoesters such as ethyl acetoacetate, ethyl butyryl acetate, ethyl benzoyl acetate, and so forth in good yields over short reaction times during the synthesis of coumarins. The methodology was further extended for the synthesis of ayapin molecules. The catalyst also shows recycle activity up to seven cycles with very good stability.

6.
Org Lett ; 19(8): 2078-2081, 2017 04 21.
Article in English | MEDLINE | ID: mdl-28375017

ABSTRACT

A highly efficient protocol of Ni(II) metal complex, [Ni(quin)2], catalyzing N-formylation and N-acylation of amines with moderate to excellent yields, using N,N-dimethylformamide and N,N-dimethylacetamide in the presence of imidazole, is described here. The protocol shows broad substrate scope for aliphatic, aromatic, and heterocyclic amines.

SELECTION OF CITATIONS
SEARCH DETAIL
...